161 related articles for article (PubMed ID: 8151795)
21. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
[TBL] [Abstract][Full Text] [Related]
22. Protective effects of nasal immunization in mice with various kinds of inactivated Sendai virus vaccines.
Miyamae T
Microbiol Immunol; 1986; 30(3):213-23. PubMed ID: 3014277
[TBL] [Abstract][Full Text] [Related]
23. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Tao T; Durbin AP; Whitehead SS; Davoodi F; Collins PL; Murphy BR
J Virol; 1998 Apr; 72(4):2955-61. PubMed ID: 9525616
[TBL] [Abstract][Full Text] [Related]
24. Variation of virulence and other properties among Sendai virus strains.
Yamaguchi R; Iwai H; Ueda K
Microbiol Immunol; 1988; 32(2):235-40. PubMed ID: 2836715
[TBL] [Abstract][Full Text] [Related]
25. Budding site of Sendai virus in polarized epithelial cells is one of the determinants for tropism and pathogenicity in mice.
Tashiro M; Seto JT; Choosakul S; Yamakawa M; Klenk HD; Rott R
Virology; 1992 Apr; 187(2):413-22. PubMed ID: 1312267
[TBL] [Abstract][Full Text] [Related]
26. Changes in specific cleavability of the Sendai virus fusion protein: implications for pathogenicity in mice.
Tashiro M; Seto JT; Choosakul S; Hegemann H; Klenk HD; Rott R
J Gen Virol; 1992 Jun; 73 ( Pt 6)():1575-9. PubMed ID: 1339465
[TBL] [Abstract][Full Text] [Related]
27. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.
Kast WM; Roux L; Curren J; Blom HJ; Voordouw AC; Meloen RH; Kolakofsky D; Melief CJ
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2283-7. PubMed ID: 1848698
[TBL] [Abstract][Full Text] [Related]
28. Inducement of respiratory mucosal immunogenicity for nasal vaccine due to amine- and amide-inactivation of parainfluenza virus type 1, Sendai.
Miyamae T
Microbiol Immunol; 1994; 38(12):937-41. PubMed ID: 7723686
[TBL] [Abstract][Full Text] [Related]
29. Combined oral/nasal immunization protects mice from Sendai virus infection.
Nedrud JG; Liang XP; Hague N; Lamm ME
J Immunol; 1987 Nov; 139(10):3484-92. PubMed ID: 2824609
[TBL] [Abstract][Full Text] [Related]
30. Augmentation of protective immune responses against Sendai virus infection by fungal polysaccharide schizophyllan.
Hotta H; Hagiwara K; Tabata K; Ito W; Homma M
Int J Immunopharmacol; 1993 Jan; 15(1):55-60. PubMed ID: 7679379
[TBL] [Abstract][Full Text] [Related]
31. Oral immunization with Sendai virus in mice.
Nedrud JG; Liang XP; Lamm ME
Curr Top Microbiol Immunol; 1989; 146():117-22. PubMed ID: 2543541
[TBL] [Abstract][Full Text] [Related]
32. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
[TBL] [Abstract][Full Text] [Related]
33. Protease activation mutants of Sendai virus: sequence analysis of the mRNA of the fusion protein (F) gene and direct identification of the cleavage-activation site.
Hsu MC; Scheid A; Choppin PW
Virology; 1987 Jan; 156(1):84-90. PubMed ID: 3027971
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.
Abente EJ; Rajao DS; Santos J; Kaplan BS; Nicholson TL; Brockmeier SL; Gauger PC; Perez DR; Vincent AL
J Virol; 2018 Nov; 92(22):. PubMed ID: 30185589
[TBL] [Abstract][Full Text] [Related]
35. Single amino acid substitution of Sendai virus at the cleavage site of the fusion protein confers trypsin resistance.
Itoh M; Shibuta H; Homma M
J Gen Virol; 1987 Nov; 68 ( Pt 11)():2939-44. PubMed ID: 2824671
[TBL] [Abstract][Full Text] [Related]
36. Human parainfluenza virus type 1 immunization of infant mice protects from subsequent Sendai virus infection.
Sangster M; Smith FS; Coleclough C; Hurwitz JL
Virology; 1995 Sep; 212(1):13-9. PubMed ID: 7676623
[TBL] [Abstract][Full Text] [Related]
37. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
[TBL] [Abstract][Full Text] [Related]
38. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.
Hall SL; Sarris CM; Tierney EL; London WT; Murphy BR
J Infect Dis; 1993 Apr; 167(4):958-62. PubMed ID: 8383726
[TBL] [Abstract][Full Text] [Related]
39. Sequence determination of the Sendai virus HN gene and its comparison to the influenza virus glycoproteins.
Blumberg B; Giorgi C; Roux L; Raju R; Dowling P; Chollet A; Kolakofsky D
Cell; 1985 May; 41(1):269-78. PubMed ID: 2986845
[TBL] [Abstract][Full Text] [Related]
40. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
